Biogen | BIIB - Trade Debtors


Biogen reported $1.79B in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
AbbVie USD 12.59B 180M Dec/2025
Acadia Pharmaceuticals USD 148.23M 8.79M Dec/2025
ALKERMES USD 334.02M 21.08M Dec/2025
Amgen USD 9.14B 432M Mar/2026
Bayer EUR 14.19B 720M Dec/2025
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Eli Lilly USD 21.18B 1.02B Mar/2026
Esperion Therapeutics USD 140.19M 21.21M Dec/2025
Gilead Sciences USD 4.91B 182M Dec/2025
Incyte USD 1.05B 27.09M Mar/2026
Merck USD 11.78B 345M Dec/2025
Moderna USD 71M 113M Mar/2026
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Novartis USD 9.6B 2.69B Mar/2026
Pfizer USD 15.84B 2.27B Dec/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 5.73B 10.1M Mar/2026
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 482M 85M Mar/2026
Sanofi EUR 397M 186.13M Dec/2025
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
Teva Pharmaceutical Industries USD 3.39B 316M Mar/2026
Ultragenyx Pharmaceutical USD 158M 45.46M Dec/2025
United Therapeutics USD 350.2M 52.5M Dec/2025
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026